Rosuvastatin plus N Acetylcysteine to Prevention of Contrast Induced Acute Kidney Injury in Patients with Low Mehran Risk Score

Authors: Mohammed Habib*

DOI: 10.23880/oajc-16000204

Volume 8, Issue 1

Abstract

Objective: Contrast induced acute renal injury is the third leading cause of hospital-acquired acute kidney injury, several protective treatments options have been developed among patients undergoing percutaneous coronary intervention (PCI). Our trial aimed to comparison between high dose rosuvastatin versus rosuvastatin plus N acetylcysteine to prevention of contrast induced acute kidney injury in patients undergoing elective PCI at Alshifa hospital in Gaza. Methods: Randomize control trial included 100 patients who undergoing elective PCI at Alshifa hospital in Gaza, Group A: (N:50) patients received 40 mg rosuvastatin orally once daily for 3 days, on dose before undergoing PCI and two dose after PCI. Group B (N: 50) patients received 40 mg rosuvastatin orally once daily for 3 days, on dose before PCI and two dose after PCI plus N-acetylcysteine 1200 mg orally twice daily every 12 hours for two days, the first dose before PCI and other 3 doses after PCI. All patients were measuring serum creatinine level, creatinine clearance and blood urea nitrogen (BUN) before PCI and (2-3) days after procedure. 

Keywords: Rosuvastatin; NAC; Contrast Induced Acute Kidney Injury

View PDF